Literature DB >> 20223934

Chemical enhancement of torsinA function in cell and animal models of torsion dystonia.

Songsong Cao1, Jeffrey W Hewett, Fumiaki Yokoi, Jun Lu, Amber Clark Buckley, Alexander J Burdette, Pan Chen, Flavia C Nery, Yuqing Li, Xandra O Breakefield, Guy A Caldwell, Kim A Caldwell.   

Abstract

Movement disorders represent a significant societal burden for which therapeutic options are limited and focused on treating disease symptomality. Early-onset torsion dystonia (EOTD) is one such disorder characterized by sustained and involuntary muscle contractions that frequently cause repetitive movements or abnormal postures. Transmitted in an autosomal dominant manner with reduced penetrance, EOTD is caused in most cases by the deletion of a glutamic acid (DeltaE) in the DYT1 (also known as TOR1A) gene product, torsinA. Although some patients respond well to anticholingerics, therapy is primarily limited to either neurosurgery or chemodenervation. As mutant torsinA (DeltaE) expression results in decreased torsinA function, therapeutic strategies directed toward enhancement of wild-type (WT) torsinA activity in patients who are heterozygous for mutant DYT1 may restore normal cellular functionality. Here, we report results from the first-ever screen for candidate small molecule therapeutics for EOTD, using multiple activity-based readouts for torsinA function in Caenorhabditis elegans, subsequent validation in human DYT1 patient fibroblasts, and behavioral rescue in a mouse model of DYT1 dystonia. We exploited the nematode to rapidly discern chemical effectors of torsinA and identified two classes of antibiotics, quinolones and aminopenicillins, which enhance WT torsinA activity in two separate in vivo assays. Representative molecules were assayed in EOTD patient fibroblasts for improvements in torsinA-dependent secretory function, which was improved significantly by ampicillin. Furthermore, a behavioral defect associated with an EOTD mouse knock-in model was also rescued following administration of ampicillin. These combined data indicate that specific small molecules that enhance torsinA activity represent a promising new approach toward therapeutic development for EOTD, and potentially for other diseases involving the processing of mutant proteins.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20223934      PMCID: PMC2860854          DOI: 10.1242/dmm.003715

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN: 1754-8403            Impact factor:   5.758


  59 in total

Review 1.  Drug-like properties and the causes of poor solubility and poor permeability.

Authors:  C A Lipinski
Journal:  J Pharmacol Toxicol Methods       Date:  2000 Jul-Aug       Impact factor: 1.950

Review 2.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Authors:  C A Lipinski; F Lombardo; B W Dominy; P J Feeney
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

3.  Identification of thermolabile Escherichia coli proteins: prevention and reversion of aggregation by DnaK and ClpB.

Authors:  A Mogk; T Tomoyasu; P Goloubinoff; S Rüdiger; D Röder; H Langen; B Bukau
Journal:  EMBO J       Date:  1999-12-15       Impact factor: 11.598

4.  TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation.

Authors:  Pamela J McLean; Hibiki Kawamata; Saadat Shariff; Jeffrey Hewett; Nutan Sharma; Kenji Ueda; Xandra O Breakefield; Bradley T Hyman
Journal:  J Neurochem       Date:  2002-11       Impact factor: 5.372

5.  Torsin A and its torsion dystonia-associated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations.

Authors:  K Kustedjo; M H Bracey; B F Cravatt
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

6.  Molecular properties that influence the oral bioavailability of drug candidates.

Authors:  Daniel F Veber; Stephen R Johnson; Hung-Yuan Cheng; Brian R Smith; Keith W Ward; Kenneth D Kopple
Journal:  J Med Chem       Date:  2002-06-06       Impact factor: 7.446

7.  IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA.

Authors:  Marcella Calfon; Huiqing Zeng; Fumihiko Urano; Jeffery H Till; Stevan R Hubbard; Heather P Harding; Scott G Clark; David Ron
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

8.  Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans.

Authors:  S H Satyal; E Schmidt; K Kitagawa; N Sondheimer; S Lindquist; J M Kramer; R I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

9.  Overexpression of human wildtype torsinA and human DeltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities.

Authors:  K Grundmann; B Reischmann; G Vanhoutte; J Hübener; P Teismann; T-K Hauser; M Bonin; J Wilbertz; S Horn; H P Nguyen; M Kuhn; S Chanarat; H Wolburg; A Van der Linden; O Riess
Journal:  Neurobiol Dis       Date:  2007-05-18       Impact factor: 5.996

10.  The Caenorhabditis elegans polarity gene ooc-5 encodes a Torsin-related protein of the AAA ATPase superfamily.

Authors:  S E Basham; L S Rose
Journal:  Development       Date:  2001-11       Impact factor: 6.868

View more
  27 in total

Review 1.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 2.  Pharmacological lifespan extension of invertebrates.

Authors:  Mark Lucanic; Gordon J Lithgow; Silvestre Alavez
Journal:  Ageing Res Rev       Date:  2012-07-06       Impact factor: 10.895

Review 3.  Engineering animal models of dystonia.

Authors:  Janneth Oleas; Fumiaki Yokoi; Mark P DeAndrade; Antonio Pisani; Yuqing Li
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

Review 4.  Designing clinical trials for dystonia.

Authors:  Wendy R Galpern; Christopher S Coffey; Alberto Albanese; Ken Cheung; Cynthia L Comella; Dixie J Ecklund; Stanley Fahn; Joseph Jankovic; Karl Kieburtz; Anthony E Lang; Michael P McDermott; Jeremy M Shefner; Jan K Teller; John L P Thompson; Sharon D Yeatts; H A Jinnah
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

5.  Decreased number of striatal cholinergic interneurons and motor deficits in dopamine receptor 2-expressing-cell-specific Dyt1 conditional knockout mice.

Authors:  Fumiaki Yokoi; Janneth Oleas; Hong Xing; Yuning Liu; Kelly M Dexter; Carly Misztal; Melinda Gerard; Iakov Efimenko; Patrick Lynch; Matthew Villanueva; Raul Alsina; Shiv Krishnaswamy; David E Vaillancourt; Yuqing Li
Journal:  Neurobiol Dis       Date:  2019-10-13       Impact factor: 5.996

6.  Earlier onset of motor deficits in mice with double mutations in Dyt1 and Sgce.

Authors:  Fumiaki Yokoi; Guang Yang; Jindong Li; Mark P DeAndrade; Tong Zhou; Yuqing Li
Journal:  J Biochem       Date:  2010-07-13       Impact factor: 3.387

7.  Electromyographic evidence in support of a knock-in mouse model of DYT1 Dystonia.

Authors:  Mark P DeAndrade; Amy Trongnetrpunya; Fumiaki Yokoi; Chad C Cheetham; Ning Peng; J Michael Wyss; Mingzhou Ding; Yuqing Li
Journal:  Mov Disord       Date:  2016-05-31       Impact factor: 10.338

8.  Improved motor performance in Dyt1 ΔGAG heterozygous knock-in mice by cerebellar Purkinje-cell specific Dyt1 conditional knocking-out.

Authors:  Fumiaki Yokoi; Mai Tu Dang; Yuqing Li
Journal:  Behav Brain Res       Date:  2012-02-25       Impact factor: 3.332

9.  The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response.

Authors:  Pan Chen; Alexander J Burdette; J Christopher Porter; John C Ricketts; Stacey A Fox; Flavia C Nery; Jeffrey W Hewett; Laura A Berkowitz; Xandra O Breakefield; Kim A Caldwell; Guy A Caldwell
Journal:  Hum Mol Genet       Date:  2010-06-28       Impact factor: 6.150

10.  Exploring the influence of torsinA expression on protein quality control.

Authors:  Kara L Gordon; Kevin A Glenn; Pedro Gonzalez-Alegre
Journal:  Neurochem Res       Date:  2010-12-16       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.